For Swiss and foreign companies, SIX Swiss Exchange is the gateway to the international and domestic capital market. A public offering and listing of securities on SIX Swiss Exchange affords a company access to a highly experienced and financially potent circle of international investors. The life sciences sector on SIX Swiss Exchange has emerged as Europe’s most important market place, with around 40 % of the European life sciences market capitalisation. The strong concentration of biotech and medtech companies in Switzerland is no coincidence: it stems from a longstanding and fruitful interactive relationship between the well-established Swiss pharma, biotech and medtech industries and the country’s financial institutions.


Another consequence of this is that investors operating in Switzerland have some of the most extensive specialist expertise in the industry. The result is a dynamic but nonetheless stable market environment, as well as rising demand for life sciences shares. As a securities marketplace with self-regulatory competencies, SIX Swiss Exchange offers its new issuers an efficient admission process that generally takes no longer than 4 weeks to complete. From the submission of the listing application straight through to the first trading day, all related decisions are taken by the competent internal governing bodies. As a result, candidates for listing on SIX Swiss Exchange benefit from the convenience of a listing out of one hand, which is characterised by short decision-making paths, flexibility and closeness to the market as well as to the customer.